Table 4.
Adjusted hazard ratio (HR) of severe hypoglycemia by combination of classes(1)
| Medication Use in Interval Antecedent to Ascertainment of Event Status |
Intensive |
Standard |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Just Oral Agents vs. Just Insulin |
0.53 |
(0.36, 0.78) |
<.0001 |
0.13 |
(0.08, 0.24) |
<.0001 |
| Oral Agents plus Insulin vs. Just Insulin |
0.93 |
(0.67, 1.31) |
0.69 |
0.97 |
(0.66, 1.43) |
0.89 |
| No Glycemia Medication(2) vs. Just Insulin |
1.47 |
(0.35, 6.1) |
0.60 |
0.15 |
(0.02, 1.09) |
0.06 |
| Insulin plus Sensitizer vs. Just Insulin(3) |
1.19 |
(0.88, 1.61) |
0.25 |
0.98 |
(0.69, 1.40) |
0.93 |
| No Insulin or Sensitizer(4) vs. Just Insulin(3) |
1.32 |
(0.56, 3.11) |
0.52 |
0.22 |
(0.08, 0.62) |
<.0001 |
| Just Sensitizer vs. Just Insulin(3) |
0.66 |
(0.45, 0.94) |
0.02 |
0.14 |
(0.07, 0.25) |
<.0001 |
| Metformin + Sulfonlyurea + TZD vs. Metformin + TZD(5) |
0.94 |
(0.72, 1.23) |
0.65 |
0.60 |
(0.32, 1.11) |
0.10 |
| 2 meds vs. 0 or 1 meds |
0.83 |
(0.46, 1.5) |
0.53 |
1.08 |
(0.64, 1.82) |
0.78 |
| 3 meds vs. 0 or 1 meds | 1.04 | (0.59, 1.82) | 0.89 | 1.82 | (1.10, 3.00) | 0.02 |
(1) All results control for the following baseline covariates: age, gender, race, education, time since diabetes diagnosis, history of neuropathy/nerve problems, BMI, A1C, albumin to creatinine ratio, serum creatinine, LDL-C, and factors used to stratify randomization (treatment groups within the BP and Lipid trials and the presence of clinical cardiovascular disease)
(2) In the standard group, there were 430 person years out of a total of 17,698 person years (2.4% of all follow-up) and in the intensive group, 35 person years out of a total of 17,130 person years (0.2%) in which participants were on no glycemia medications.
(3) Model also controls for use of AGI’s, meglitinide, incretins and sulfonylurea.
(4) Participants in this group were prescribed sulfonylureas, AGI, meglitinide, incretin or exenatide.
(5) Model also controls for use of Insulin, AGI’s, meglitinide, incretins and sulfonylurea.